Melanoma/Solid Tumor Cell Therapy Research Position
HonorHealth Research Institute
Scottsdale, Arizona
As part of a non-profit healthcare system with nine hospitals and primary teaching affiliate for the new Arizona State University School of Medicine and Advanced Medical Engineering and Center for Translational Science, the Division of Cancer Research is seeking Board Certified Medical Oncologists with clinical research expertise/interest in
Melanoma and Solid Tumor Cellular Therapy to join a Cutaneous Oncology Program
Join the preeminent Phase 1 Oncology Drug Development Program in the Southwest US
HonorHealth Research Institute (HRI)
HRI is seeking a Board-Certified Oncologist to join the Melanoma and Solid tumor Cellular Therapy Program which sees patients with all types of advanced cutaneous malignancies for both standard of care and clinical trial treatments in collaboration with the HonorHealth Dermatology Residency Program. The program has a special focus on uveal/ocular melanoma with multiple clinical trials and translational research programs focused on this rare tumor. The Research Oncologist will partner with the Melanoma Medical Oncologist and will independently lead Phase 1 & 2 clinical trials. The successful candidate will have the opportunity to lead early phase clinical trials and participate in novel cellular therapy and bispecific antibody trials.
HonorHealth is the primary clinical affiliate for the new Arizona State University School of Medicine and Advanced Medical Engineering who will be accepting the first class of medical students in 2026; This creates an exciting opportunity to help build a unique medical school. As a dual degree program, the focus for the ASU SOMME will go beyond traditional course curriculum and will foster innovation through the use of artificial intelligence, data science, and other advanced technologies in healthcare.
HRI’s new Center for Translational Science will use new techniques and disciplines rooted in the molecular (DNA) basis of disease. The new Center for Translational Science will build on the Research Institute’s expertise in developing first-in-human clinical trials, immune-system therapies, cellular therapies, targeted therapies and others to develop treatments that attack diseases, while minimizing negative side effects that might compromise a patient’s health. The new center is seen as a worldwide bridge among scientists, researchers and physicians in their pursuit of new diagnostics and therapeutics to benefit patients.
HonorHealth Research Institute impacts the value and quality of patient care by accelerating innovation, while seamlessly integrating the latest science, including:
The successful candidate will engage with community hematology/oncology partners in the Phoenix metropolitan area supporting expansion of access to current bispecific antibody options for lymphoma and multiple myeloma with a focus on disease or therapeutic approaches.
Responsibilities:
Why Scottsdale?